Although the standard of care for HER2-positive breast cancer typically involves neoadjuvant chemotherapy, a multidisciplinary team, including breast surgeons, oncologists, and radiation oncologists, elected that performing a definitive surgical oncological resection, a modified radical mastectomy (MRM), in this clinical setting was justified and reasonable. The gene discussed is ERBB2; the disease is breast carcinoma.